Zepbound (Tirzepatide)

If you read the Mounjaro page, you already know the story of tirzepatide — the dual-action medication that targets both GLP-1 and GIP pathways. The diabetes trial results showed weight loss numbers that rivaled dedicated weight management drugs.

Zepbound is what happened next. Eli Lilly took the same molecule and ran it through a massive set of weight management trials, got it approved specifically for that purpose, and then kept going — adding an approval for obstructive sleep apnea that nobody saw coming.

This page covers what Zepbound is, what makes it different from Mounjaro (same drug, very different product), what the clinical trial data shows, and who it’s designed for. If your goal is weight management and your provider has mentioned tirzepatide, this is the page that matters most.

---

The Basics

Zepbound is made by Eli Lilly. The active ingredient is tirzepatide — the same molecule used in Mounjaro (Lilly’s diabetes product). Same company, same drug, different approvals and different purposes.

FDA-approved indications:

1. Chronic weight management — for adults with a BMI of 30 or higher, or BMI of 27+ with at least one weight-related health condition. Used alongside reduced calorie intake and increased physical activity. (November 2023)
2. Obstructive sleep apnea (OSA) — for moderate-to-severe OSA in adults with obesity. (December 2024)

What Zepbound is NOT approved for: Type 2 diabetes. That’s Mounjaro. If your primary concern is blood sugar control and you have diabetes, the Mounjaro page covers the product designed for that purpose.

What Makes It Different: The Dual-Action Mechanism

Zepbound is the same molecule as Mounjaro, so everything about the dual GLP-1/GIP mechanism applies here too. It targets two hormone pathways instead of one — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Both help regulate appetite and metabolism, but through slightly different pathways. The dual targeting is why tirzepatide’s weight loss numbers look different from semaglutide’s.

For the full science on how this dual mechanism works, see our Deep Dive: GLP-1 vs. Dual Agonists page.[1]

---

How It’s Delivered

Zepbound uses the same single-dose, pre-filled pen system as Mounjaro — one injection per pen, then you discard it. Same color-coded system too:

Each box contains 4 pens (one month’s supply at one injection per week). The injection goes under the skin in the abdomen, thigh, or upper arm. Same day each week, any time of day, with or without food.

Lilly has also introduced single-dose vials for some dose levels (such as 2.5 mg, 5 mg, and 10 mg) — designed for use with a syringe rather than a pen. These provide an additional option, particularly in healthcare settings or for patients who prefer vials. Your provider and pharmacy will determine which format you receive.[2]

---

Dosing: How It Works

The dosing schedule is identical to Mounjaro — the same six-step ramp-up with 2.5 mg increments every four weeks.

Key things to know:

• Each increase is 2.5 mg at a time — a gentler step-up than Wegovy’s escalation schedule.
• Not everyone needs the maximum dose. The SURMOUNT trials showed meaningful weight loss across all dose levels. Your provider will find the dose that balances effectiveness with tolerability for you.
• The 2.5 mg starting dose exists purely for adjustment. Don’t be concerned if nothing dramatic happens in the first month.
• If you miss a dose, take it within 4 days. If more than 4 days have passed, skip it and take the next dose on your regular day.[3]

---

What the Research Shows

Zepbound was studied in the SURMOUNT trial program — one of the largest and most comprehensive clinical trial programs for any weight management medication. The results consistently stood out, including the first head-to-head trial against semaglutide.

SURMOUNT-1: The Headline Trial

This is the trial that established what tirzepatide can do for weight loss.

• Who: 2,539 adults with obesity (or overweight with a weight-related condition), WITHOUT Type 2 diabetes
• What: Zepbound 5 mg, 10 mg, or 15 mg weekly vs. placebo, all with lifestyle changes
• How long: 72 weeks (about 17 months)

The results:[4]

Look at the 15 mg column: more than half of patients lost at least 20% of their body weight. For someone starting at 250 lbs, that’s 50+ lbs — in a little over a year. Even the lowest dose (5 mg) produced 15% weight loss. These numbers were unprecedented for any medication.

SURMOUNT-5: Head-to-Head Against Semaglutide

This is the trial that answered the question everyone was asking: how does Zepbound compare directly to Wegovy?

SURMOUNT-5 enrolled 751 adults with obesity and randomized them to either tirzepatide (up to 15 mg/week) or semaglutide (up to 2.4 mg/week) for 72 weeks.

The result:[5]

Tirzepatide produced significantly more weight loss than semaglutide — about 47% more. This was the first time the two medications had been directly compared in a dedicated weight management trial, and the result was decisive.

Important context: This doesn’t mean semaglutide is a bad medication. A 13.7% weight loss is still a strong result by any standard. But for people and providers trying to choose between the two, this trial provided clear comparative data that hadn’t existed before.

SURMOUNT-3: Combined With Intensive Lifestyle Intervention

This trial added a 12-week intensive lifestyle intervention (very low calorie diet of ~800 calories/day) before starting tirzepatide. Patients lost about 6.9% of their body weight during the diet phase, then continued to lose weight on medication.

The combined result: Total weight loss reached 26.6% at 72 weeks. That’s one of the highest weight loss numbers ever recorded in a clinical trial for any medication.[6]

The takeaway mirrors what we saw with Wegovy’s STEP 3 trial: the medication works, and it works even better when combined with real lifestyle support. They amplify each other.

SURMOUNT-4: What Happens When You Stop

This trial asked the uncomfortable question: what happens to the weight loss when you stop taking the medication?

Patients on Zepbound were randomized at week 36 to either continue the medication or switch to placebo. Those who continued lost an additional 5.5% of body weight. Those who switched to placebo regained about 14% of their body weight over the next year.[7]

This is an important data point for anyone thinking about whether this is a temporary or long-term medication. The weight loss requires ongoing treatment to maintain — which is consistent with how we treat other chronic conditions.

SURMOUNT-OSA: Sleep Apnea

This was the unexpected one. Obstructive sleep apnea (OSA) is a condition where your airway repeatedly collapses during sleep, causing you to stop breathing briefly — often dozens of times per hour. It’s strongly associated with obesity, and it was widely assumed that weight loss alone would improve it. But nobody had run a rigorous trial to prove it until now.

SURMOUNT-OSA enrolled 469 adults with moderate-to-severe OSA and obesity. After 52 weeks on tirzepatide:

• The frequency of breathing interruptions during sleep (measured by something called the AHI — basically counting how many times per hour your breathing stops) dropped by 20-24 events per hour
• About half of patients improved enough to be reclassified from “severe” to “moderate” or “mild” sleep apnea
• Average weight loss was approximately 18-20%[8]

In December 2024, this trial led to Zepbound becoming the first medication ever approved specifically for obstructive sleep apnea. That’s not a GLP-1 first — it’s a first for any medication, period.

---

Side Effects

The side effect profile follows the same GI-dominant pattern as other GLP-1 medications. Most side effects are gastrointestinal, peak during dose escalation, and improve over time.

The Numbers (from SURMOUNT-1)

Context that matters: The majority of GI side effects occurred during dose escalation and decreased over time. Most were mild to moderate. The percentage of people who stopped Zepbound because of side effects ranged from 4-7% across dose groups — real, but relatively low. The gradual 2.5 mg dose increments help make the ramp-up more manageable than the larger jumps in some other GLP-1 medication schedules.[9]

---

The Zepbound vs. Mounjaro Question

Same molecule. Same pen. Same manufacturer. Different product. Here’s the comparison:

The same insurance dynamics we saw with Wegovy vs. Ozempic apply here. The weight management product (Zepbound) has more variable insurance coverage than the diabetes product (Mounjaro). If you have Type 2 diabetes and want both blood sugar control and weight loss, Mounjaro is often the easier product to get covered — and you’ll likely see significant weight loss on it anyway.

If you DON’T have diabetes and your goal is weight management, Zepbound is the appropriate product. Coverage is improving, and Lilly’s savings programs (detailed below) can make a meaningful dent in the cost.

Never use both simultaneously. They’re the same drug — doubling up would mean doubling the dose, which is dangerous.[10]

---

Cost and Access

What Zepbound Costs

The Lilly Savings Card

If you have commercial insurance that covers Zepbound, Eli Lilly’s savings card brings your copay to as little as $25 per month (up to $150 in savings per fill). The card is valid through December 2026.

If your commercial insurance does NOT cover Zepbound, the savings card can still reduce your cost to $399–$549 per month through LillyDirect.[11]

Who qualifies: People with commercial insurance and a prescription for an FDA-approved use. Who doesn’t: Medicare, Medicaid, TRICARE, VA, and other government insurance — federal rules prohibit manufacturer savings cards for government programs.

Medicare Coverage

Medicare Part D has historically not covered anti-obesity medications. That’s changing:

• Zepbound’s OSA indication opened a new coverage pathway — Medicare may cover it when prescribed specifically for obstructive sleep apnea with obesity.
• Through the BALANCE model (announced by CMS), Medicare is expected to offer tirzepatide coverage at approximately $50/month for eligible beneficiaries starting in mid-2026. This would be a dramatic shift from the current out-of-pocket reality for Medicare patients.[12]
• As always, coverage varies by plan. Check with your specific Medicare Part D plan for current details.

If You Can’t Afford It

Eli Lilly’s Lilly Cares Patient Assistance Program provides medications at no cost for eligible uninsured patients. Contact Lilly Cares at 1-800-545-6962 or visit lillycares.com.

---

Storage

Same storage rules as Mounjaro — same drug, same pen, same requirements. Since each pen is single-use, there’s no “days after first use” window to track.[13]

---

The Bottom Line

Zepbound brought tirzepatide’s dual-action approach to the weight management space — and the results speak for themselves. Average weight loss of 20% at the highest dose. More weight loss than semaglutide in a head-to-head trial. The first-ever medication approval for obstructive sleep apnea. Combined with lifestyle changes, some of the highest weight loss numbers ever recorded in clinical trials.

If your goal is weight management and you don’t have Type 2 diabetes, Zepbound is one of the most effective options available today. The dual GLP-1/GIP mechanism, the flexible dosing with six dose levels, and the growing body of clinical evidence make a compelling case. The remaining challenge is access and cost — but that picture is improving, especially with new Medicare pathways and manufacturer programs.

For the diabetes story with this same molecule, the Mounjaro page covers the SURPASS trials and what tirzepatide looks like when it’s specifically approved for Type 2 diabetes.

---